Advertisement


William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL

NCCN 2019 Annual Congress: Hematologic Malignancies

Advertisement

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, offers commentary on the debate about evolving strategies in first-line chronic lymphocytic leukemia, the clinical trials on such agents as ibrutinib, BTK inhibitors, and venetoclax, and the interest in chemoimmunotherapy as a fixed duration treatment.



Related Videos

Multiple Myeloma
Immunotherapy

Jorge J. Castillo, MD, on Evolution of Therapy for Relapsed/Refractory Multiple Myeloma

Jorge J. Castillo, MD, of Dana-Farber Cancer Institute, discusses the many advances in treating relapsed and/or refractory multiple myeloma, including novel immunomodulators,...

Lymphoma
Immunotherapy

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Richard I. Fisher, MD, of Fox Chase Cancer Center, discusses the improvement in survival for patients with follicular lymphoma, new targeted biologic agents providing alterna...

Leukemia
Immunotherapy

Nitin Jain, MD, on CLL: Is There a Role for Chemoimmunotherapy?

Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, discusses the debate on evolving strategies in first-line treatment of CLL.

Hematologic Malignancies

Andrew D. Zelenetz, MD, PhD, on The Era of Therapeutic Biosimilars: What You Need to Know

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the nature of biologic molecules and their importance in future therapeutic innovation.

Myelodysplastic Syndromes

Rafael Bejar, MD, PhD, on Myelodysplastic Syndromes: Advances in Personalized Therapeutic Approaches

Rafael Bejar, MD, PhD, of the University of California, San Diego Moores Cancer Center, discusses the tailored nature of MDS treatment, including somatic mutations that could...

Advertisement

Advertisement



Advertisement